Filtros de búsqueda

Lista de obras de

Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME

artículo científico publicado en 2020

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

artículo científico publicado en 2020

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials

artículo científico publicado en 2019

Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial

artículo científico publicado en 2020

Effects of dapagliflozin in heart failure with reduced ejection fraction, and COPD: An analysis of DAPA-HF

scientific article published on 23 December 2020

Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials

artículo científico publicado en 2020

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial.

artículo científico publicado en 2019

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial

scientific article published on 29 March 2020

Empagliflozin restores the integrity of the endothelial glycocalyx in vitro

artículo científico publicado en 2019

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

artículo científico publicado en 2021

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials

artículo científico publicado en 2020

The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of LEADER and SUSTAIN 6 trials

scientific article published on 06 May 2020

Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions

scientific article published on 10 October 2019

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda